• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

News

Follow @CloudPharm
Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
​

COO Don Van Dyke to describe company technology and achievements in designing small molecule and peptide agents.

Research Triangle Park, NC, April 30, 2019

RESEARCH TRIANGLE PARK, NC, USA, April 30, 2019  -- Don Van Dyke, COO of Cloud Pharmaceuticals Inc., an AI-based drug design company, is being featured as a speaker at several conferences in May. Van Dyke will discuss how Artificial Intelligence-based drug design is helping to transform the creation of new medicines.

During his sessions, Van Dyke describe Cloud Pharmaceuticals’ Quantum Molecular Design process, which enables faster progress at lower cost and a higher success rate than traditional methods, even with difficult targets. He will reference the company’s work with companies such as GSK to advance from target to lead molecule in months rather than years.
 
Schedule:

  • 4th Drug Discovery Nexus Summit 2019 May 16-17, 2019, Boston, MA.
 
  • 8th DRUG DISCOVERY INNOVATION PROGRAMME May 21, 2019, Boston, MA
 
  • PHARMA AI May 23 - 24, 2019 London, UK
 
“We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance,” Van Dyke explains. “Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.”
About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com